Nov. 22, 2022

629: Can We Solve Our Mental Health Crisis via Psychedelic Pharmaceutical Medicines?

Psycheceutical is focused on developing innovative solutions to society's most pressing problems using psychedelics as medicines. Through their research, they've found that psychedelics are a powerful tool for treating mental health issues like depression and anxiety.

On today's episode, I'm joined by Chad Harman, Chief Executive Officer of Psycheceutical, who answers that very question and how his team at Psycheceutical is helping blaze the trail forward in this space.

Psycheceutical is focused on developing innovative solutions to society's most pressing problems using psychedelics as medicines. Through their research, they've found that psychedelics are a powerful tool for treating mental health issues like depression and anxiety.

They believe that psychedelics have the potential to be used as a therapeutic aid for people with conditions such as post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), and even schizophrenia—all without the side effects of current pharmaceutical medications.

In this conversation, we discuss:

-The current state of our mental health crisis and what it's doing to us as a society

-How psychedelic pharmaceuticals can help treat depression and other disorders

-How Psycheceutical is making this happen now instead of later

- How psychedelic medicines can help people with mental health problems

- Why there are so many misconceptions around these drugs

Learn more about your ad choices. Visit

Studio SponsorBNC: Proven sales and messaging strategies that WIN -

Support our Sponsors!

Support the program with a one-time donation or join our Patreon!

Take our audience survey for a chance to win a "Don't Hurt People, Don't Take Their Stuff" bumper sticker! 




Brian Nichols  0:07  
Can we solve our mental health crisis by providing safe and effective deliveries of psychedelic pharmaceutical medicines? Yeah, let's talk about that thing on winning arguments. We're teaching the basic fundamentals of sales and marketing and how we can use them to win in the world of politics, teaching you how to meet people where they're at on the issues they care about. Welcome to The Brian Nichols Show. Well, happy Tuesday, Brian Nichols, you're on The Brian Nichols Show. Thank you for joining us on a horse. In a fun filled episode. I am as always your humble host joining you live from our Stratus ip studio. You're in lovely Eastern Indiana. Don't let cyber attacks or outdated Business Technology put your company at risk. Learn more at the Brian Nichols forward slash Stratus ip Stratus ip Business Technology simplified. Yeah, well, let's talk about the idea, folks for today's episode of being able to address our mental health issues. And frankly, it's it's a crisis that we're facing here in America. But let's address it in a different way we talk about here on the show addressing problems at the root of their their causes versus trying to address symptoms. So today, we're going to be focusing specifically how we can go ahead and address mental health using in this case, psychedelic medicines, but also making them in the world of pharmaceuticals. But before we get there, gotta go ahead and give a shout out to today's sponsor, and that is the Libertarian Party of Illinois, folks, the mission of the Libertarian Party of Illinois is to elect libertarians to public office and to move public policy in a libertarian direction. The LP of Illinois believes that everyone owns themselves, and that no bureaucrat knows better than you what you need or what you want tech, maybe like psychedelic pharmaceuticals. But when peaceful people engage in voluntary cooperation, the most number of people are served. And if you agree with that message, help us restore Liberty up in Illinois, and LP and help bring back peace and liberty to both Illinois and the United States. In our lifetimes. One more time LP Alright, so yeah, let's talk about psychedelics. I can't do it by myself today. Joining me from Cycas su tickle. Chad Harman, welcome to the program.

Chad Harman  2:31  
Thank you, Brian. Pleasure to be here. And you said onpoint love it.

Brian Nichols  2:35  
Alright, see, we the audience doesn't get to appreciate Chad that the stuff that we do behind the scenes and behind the scenes, I went through saying the name psychoanalytical about seven times to make sure I got it right, because I am the product of government education. So unfortunately, I was more focused on learning. God knows what arts and crafts and I was trying to learn the English language. So forgive me. I'm sorry, guys. But it took me a little time. But thankfully, God, right the first time, Chad, you're doing amazing work over us like a surgical and you're helping address mental health. And it is specifically an issue right now that we are facing in America. It is at all time, crisis levels and truly crisis levels after you watch what has happened over the past three years, folks being locked in their homes and being told, well, sorry, you're on essential businesses shut down kids watching their entire futures completely destroyed on the whims of some government bureaucrats. Now, that's all obviously conversations for a different podcast. But Chad, you're addressing right now, where we see mental health being a main crisis point, a different way, a different way of doing things. We'd like that here in the show. Talk to us about the approach you're taking over. It's like a surgical.

Chad Harman  3:49  
Yeah, I mean, going back to those stats, you know, certainly, you know, coming out of the COVID 19 pandemic. You know, one out of five Americans experienced mental illness each year, but he is what some of our medical advisory board members, some of the doctors we've spoken to all around the US, and certainly with one of our own Dr. Gillian bales, who's on the board of the NCAA, he says it's more like one and three you know, it's it's such a staggering number. And we can even point to a number of Como comorbidity issues now we're starting to see where, you know, cardiovascular disease, from depression, anxiety, PTSD, are really starting to take take heart, we're seeing much more of those disease states. Start start to take root if you will. So for us, you know, what we've seen in even prior to engaging in psychedelics you know, there's been Decades of research have shown that psychedelic medicines have powerful potential for life saving mental health treatment However, for a widespread adoption, psychedelic medicines need to be delivered in the same way pharmaceuticals do with targeted control, hence the name psychoanalytical. We're bringing the best out pharmaceuticals, with psychedelics, right? So Psych is critical. So we add like a cynical world bio biopharmaceutical company, bringing a much needed focus on precision dosing technology to the mental health industry. You know, our mission, Brian, is to develop safer and more effective tools for combating the mental health and addiction crisis we face today coming out of the pandemic. And even right, we can make the argument before the pandemic.

Brian Nichols  5:41  
So I was on it was back in I told you, I can't remember the date, I was actually looking here as we were off camera, I can't remember the date was our friends over a micro dose is either 2020 or 2021. Darn you COVID messing up with my concept of time. But we joined our friends there, we hosted a panel, and we talked about the use of psychedelics. And we talked specifically in that panel about our friends over in the armed services. And our friends also who served overseas are now facing PTSD and all sorts of other demons that they brought back over when they came home. So we saw and this goes hand in hand with the overall general conversation about mental health, that has become a just just tragic, tragic epidemic that I don't think is nearly getting enough airtime that needs to be getting. And frankly, that's why I was so honored to hold that that panel and to be able to speak to a lot of vets, frankly, who are going out and dealing with this every single day not just themselves, but with their cohorts that they served with overseas and now coming home and traveling having to face those those demons. That's the hardest part for them and being able to find solutions. So I know that we were talking about some solutions. In that case, what are you seeing right now maybe any interest from our friends in the veteran community who are looking for some alternatives using cycle vehicles?

Chad Harman  7:08  
Yeah, I mean, we're seeing Case in point one of our competitors in the industry, they're in Carcillo. You know, he's he's leading up company on on traumatic brain injury. And, you know, he's got a lot of individuals that are, you know, in the veteran community that supporting him in his efforts, and we're seeing more veteran, especially at the conferences, more veteran, various organizations come and support and really start to get engaged, you know, not only at the grassroots level of local cities and communities, but you know, states and now at the government level, they're really pushing it up, and really starting to hear their voice at the congressional level. So, you know, they're at the heart of what we do. As I mentioned, you know, my father is a is a former Vietnam veteran, my grandfather was World War Two in my great grandfather was World War One. So they're at the heart of who we are. It's like a spherical. Many of us here, have family or friends or loved ones that have been in the military. And we hold them dear, near and dear to our heart. And obviously, they're our first line of defense, as a nation. So you know, we want to honor and protect them, and know that we want them to come back in a safe environment where they can come back and heal and be reintroduced into society be productive members.

Brian Nichols  8:34  
Now, we could talk about maybe not sending our friends overseas, but that's a whole again, other conversation for a different podcast. But thank you for Yeah, addressing a very real problem, Chad and let's also talk about, I guess, the uphill battle you're facing because this is something I'm sure half of the audience is looking at and listening to with a raised eyebrow like I'm I'm old enough to remember when it was determined it was fact that marijuana killed your brain cells. I remember seeing that study. And by the way, that study was done on monkeys where they were pumping them with THC and gas masks, and they literally suffocated the monkeys to death. And what ended up happening was the brain damage that the monkeys received wasn't from the THC. It was from the lack of oxygen, which believe it or not, when you don't have oxygen going to the brain, you might suffer some brain damage. So yeah, I'm I'm used to the propaganda. I think a lot of us are used to the propaganda but let's be real Chad. A lot of folks out there. They're still weary about this stuff. Like they hear they hear psychedelics, and they instantly just think of the scene and Tenacious D in the pic of destiny where Jack Black is floating down the magic mushroom river where rainbows and unicorns are everywhere. And he's talking to public, you know, the Sasquatch, so, I mean, how are you approaching those folks who are just so vehemently against this idea of using psychedelics in our medicine, specifically in the world of pharmaceuticals

Chad Harman  10:00  
Yeah, great question, one that we're facing as, as an industry. And what we're doing is we're showing, you know, very viable clinical results as a result of, you know, several clinical trials being in the phase two and phase three, where we're now starting to dose patients. But even beyond that, what we saw, even in the 50s, and 60s, were mean really remarkable results. For patients dealing with, in certainly many cases, they were life threatening illnesses, where this was the only means in measure where an individual can stop the suffering and the pain or anguish with with knowing that they have a terminal illness. And what we saw through Michael Paul, and, and his Netflix video, was the fact that in the 50s, and 60s, you know, we had this, these these molecules that were very profound, they were able to treat many of the mental health disorders that we're now faced with today. And we now know that, especially as a result of a recent article from University of London, that showed our traditional treatment methodology with SSRIs, and the serotonin receptors, being you know, the result of where the the primary predominantly issues reside, that that is completely false, that narrative has been disproven. And now we really have to take a look back and say, what is the data showing? What are the clinical results showing? Well, now with you know, phase two inhuman, and phase three trials, with with maps, with Compass pathways, I mean, they're tremendous results. And the data shows conclusively that it is, it is in a therapeutic sense, overcoming a lot of those depression, anxiety, Pts disorders, where, you know, previously, it's 20, to 30%, with traditional SSRIs, and cognitive behavioral therapy, so that the data doesn't lie, right. And that's what I would point to.

Brian Nichols  12:05  
It's tough in this industry, I'm sure. Not just facing folks who have stigma, but also you're facing a lot of uphill battle when it comes to the the legal battles that you're going to be facing, I'm sure you have been facing. And we talk about this all the time, in terms of the way we approach solutions here at the show The reason, and this isn't necessarily the reason but you know, fundamentally a reason we've taken such a niche where we're talking not just to our liberty friends, but also specifically your business owners, your entrepreneurs is that we see that in order to get your ideas into action, right, what's the most effective means to do so. And by and large, with almost zero exceptions, you're going to find that that's going to be in the private sector using something in the free market space. And when government sets these rules that they do not just go away, they're there forever. They put roadblocks in the way for very well intentioned and well suited individuals in the free market who are trying to address these problems from being able to do so now I see that as an issue, because it's keeping folks from actually innovating having real solutions to the problems we see out there. Number one, but number two, the other issue I see is that it keeps bad ideas and bad solutions in place. It embraces and solidifies the status quo, which as a sales guy, Chad, I am vehemently against. So talk to us about that. How are you facing that? over it? It's like a surgical.

Chad Harman  13:44  
Yeah, I mean, so, you know, again, what the predominant issues that we were facing as an industry are certainly some of the known side effects, right? We're considering these profound psychogenic effects, right? We've got nausea, we have vomiting, right, in terms of an overall sales pitch, right? Those are things that, you know, individuals really, for most of us do not want to experience, right. That's traumatic in itself. And so it's like a surgical, what we're doing and what we created, our company around is, you know, having very profound remarkable delivery technologies to alleviate a lot of those concerns. So up to now, you know, there have been significant medical and really technological limitations, you know, keeping psychedelics from being safe, effective, and certainly widely accessible. So again, we wanted to deliver these, you know, not in the traditional, hey, take, you know, two caps and a stem and tell me how you feel and go more experienced that we truly want him to target and control and wanted to, you know, really give the patients the comfort knowing that they're going to be delivering a dosage form that is widely acceptable, and it's going to give them the best experience It's possible, but also it's gonna give this the FDA certainly the DEA, right, because we're dealing with a DEA that these molecules are scheduled one, meaning they have no medicinal value. So we need to show to the regulatory bodies, that these are safe and effective, and they can be targeted for control. And certainly, you know, we believe with our patented technologies that we've solved the dosing problem, where we can alleviate a lot of the psychogenic effects, so that we can increase the user adoption to, you know, adolescents, right who need these right, going back to your earlier point, in the top of the hour, we're talking about individual or adolescents at school, where they're the wearing the mask, they're not, they're, you know, six feet separated from, from their classmates, you can't touch them, you're not having that intimate touch that we know that is very valuable to humans, right. So now you're incorporating that sector of the population, you're also incorporating the the elderly population who, you know, really don't want that psychogenic very profound effect, right, because of some of the, the, the the other conditions that they're dealing with. So we as like psychedelics are really bridging the gap of bringing everybody into the mainstream by providing a solution of targeted control without the side effects. And we're also you know, taking a attract, if you will, and approach with the FDA saying, Hey, we're really targeted, we're really focusing on alleviating a lot of those concerns. So that's what we're doing. It's like, sexy to

Brian Nichols  16:42  
talk to us about the future. And let's maybe get outside of the world of mental health, because, and not that I don't want to talk about mental health. But I think we've spent a lot of time here. And I think there's also other areas, that we're finding that the psychedelics are having a lot of success in helping in terms of being alternatives to your traditional pharmaceutical medicines. Can you speak more about that a little bit?

Chad Harman  17:05  
Yeah, I mean, we're seeing, you know, tremendous progress with, you know, multiple sclerosis, Alzheimer's, Parkinson's, even traumatic brain injury, CTE, right. Those are the areas that we're seeing, you know, tremendous, positive results outside of traditional mental health, right. I mean, we even we can relate it back to aging brain. Again, going back to one of our doctors, Dr. Thomas Campbell, he's a cardiologist out of out of Nashville. And he is a big proponent, that a lot of mental health disorders, and even neurological and cardiovascular issues, stem from, you know, mental health disorders. So we're seeing that if we can, we can attack the problem at its root, which a lot of it stems from mental health disorders that then go into neurological and cardiovascular and again, going back and aging issues, if we can attack it at the root cause, which we know by based on clinical results, that these early results show that if we can combat that, then we're we're alleviating a lot of downstream effects as it relates to aging, neurological disorders, and cardiovascular disease states. So you know, that's, those are the other areas that we're certainly focused on. And I wouldn't even point to even an article recently, as of, I think, a week or two, Apple put it out that an individual that that was, you know, they were, you know, unable to walk, and they, they were paralyzed from the waist down. And so this individual went to a concert out in Colorado, they ingested a bunch of psilocybin mushrooms, and during the conference was starting to feel that their extremities start to move again, and is now walking in and using their limbs. So again, remarkable results. And we're just starting to really understand the powerful, remarkable results of of what these compounds can do.

Brian Nichols  19:10  
All right now, is the part where I get banned. I'm gonna put my tinfoil hat on because like, what, I feel like Peter Griffin and Family Guy, where he's like, Why were we funding this but like, let's be real. Why were these all put on? The was it class one substance list?

Chad Harman  19:31  
Schedule One. Yep, schedule one.

Brian Nichols  19:33  
Excuse me. Yeah. But like, why? Like if it were, were people that afraid of not knowing? or, dare I say the conspiracy hat comes on, like, Are there possibly nefarious reasons for these drugs, psychedelics being classified and scheduled this way? I mean, goodness, let's, we just saw what happened over the past few years with the pharmaceutical reach in terms of their ability to in fluence not just government officials but also anybody in media Goodness gracious, it became a joke, every commercial before the commercials would go, any new segment would end with brought to you by Pfizer, like you saw that that was what just happened over the past two years, man. I mean, go back 100 years. Is it possible? That's all happened before? And that's why like they knew this stuff work. They just tried to hide it.

Chad Harman  20:26  
Yeah, that's, that's a that's a very taboo subject. Right. So especially somebody in this industry. But you know, what I will say, is certainly, that the data for many years is supported. But I would even go back to, you know, even looking back at marijuana, which I had the fortunate opportunity of being in for several years. And, you know, looking back in the early 20s, you know, and what was our, what was our pharmacy at that point in time? Where did what what compounds were worked with? We worked a lot of in marijuana, it was, it was very powerful and profound on many ailments across the board. It was kind of almost the cure all catch. All right. And then, and then suddenly, we ran up against, you know, legislative or what I would say the the DEA at that point in time, which was really adamant about alcohol use, right? Well, once once the powers that be started supporting alcohol, and we legalized it, well, then you had a whole bureaucracy in a federal body that now had to advocate for themselves and their positions, right. So then hence, here comes the, the propaganda against marijuana. And again, fast forward to the 50s and 60s, we were seeing that, you know, it was taking a, a whole movement of so called hippies from the 50s and 60s, and really starting to cap to, to go against the establishment of anti war. Right now you're having these hippies, that are having these profound experiences. And they're trying, and they're saying, hey, wait a minute, maybe war is not good. Why are we truly in Vietnam at this point in time, and that was against, you know, government, right, that was going to go against big government. So then you had, then, you know, the establishment saying, Alright, we're gonna reschedule these, these are drugs that again, going into the propaganda, it's frying the brain, then you had the 80s, where we had the rise of SSRIs, coming into focus, right from big pharma. But then you have the war on drugs, right? You have the Reagan administration, that really pushed forward and said, Hey, we really need to take a hard stance on on these drugs. They're, they're, they're molding and shaping, and ruining our paratus adolescent and those individuals that are exploring, you know, and obviously having the crack cocaine epidemic during that time. So, you know, to your point, Brian, you're going up against, you know, federal regulations, you're going up against this big, big business, and it's a perfect storm. And where I think we're at now, is we're reaching a precipice as a society, where we're seeing this global, this global truth that says, should we have locked down? Should we have taken the stance that we should have given the data? You know, again, I always love to go back, you know, a lot of my leadership, and how I ran based businesses were surrounding data and statistics, how do we measure and monitor the success of an organization? And how do we achieve a corporate strategy? Well, you need data and statistics. And so taking a step back, looking at COVID, we're seeing that, you know, 99.7 of the population was unaffected by by COVID, and wouldn't be unaffected. I mean, we weren't seeing the death rates, and that we were supposed to see. Right. And so that that approach, then goes back into, you know, how much was that government overreach? And how much of it is we as a society, taking back the reins and starting to say, hey, you know, what we have true, we have true compounds that can fix these issues, like psychedelics that can, you know, that can address these mental health issues coming out of it. So, I know that's a long winded answer. It's a very complex issue, but I think they're very targeted focus to, you know, where we need to address these and I think we as a society are doing that and certainly work we it's it's like a sudoku or or forefront of addressing those issues?

Brian Nichols  25:02  
Well, if there's one thing as we go towards final thoughts today, I'll start things off here, Chad, and that is over the past two years, or maybe the past 20 minutes, if anything you have learned it is to, in fact, question everything. So with that, head over to the Brian Nichols forward slash shop, where you can go ahead and get your own question anything or everything bumper sticker, Yeah, question anything? No question everything. bumper sticker. And these make great Christmas gifts. By the way, folks, I know Christmas is right around the corner. It's just about a month away. So if you're gonna go ahead and look for a gift for that Liberty fanatic in your life, who is looking to in fact, question everything, go into the Brian Nichols forward slash shop, go check out our friends over at proud libertarian, and do yourself a favor use code TBNS at checkout and of course, continue to question everything Chad, what do you have for us for final thoughts today?

Chad Harman  26:00  
Yeah, I just want to leave your your your listeners with a message of hope that we are pushing forward towards legalization. We are you know, we are going to provide we know we are going to provide a viable solution to the mental health crisis. And even again, to neurological disorders, we hold great promise there as well. In terms of, you know, other comorbidities, we're going to have a solution that we're going to bring to the market, and something that's going to be safe and effective for for the users. And you know, I would love for your audience to continue to follow us and support us in the message of, of, you know, getting these these very profound, remarkable molecules through the approval process. And we look forward to helping you know those that enjoy your show so much, Brian.

Brian Nichols  26:54  
Perfect. Chad, thank you very much for joining us today. And folks, if you enjoyed today's episode well you know the drill Please go ahead, give today's episode a share. And when you do, please go ahead and tag yours truly at be Nichols liberty. And also you can go ahead and when you share today's episode, you can not only find the audio version, which I know 90% of you guys are going to be listening to the show with over there. And again, anywhere you listen to your podcast but also you can share the video version of the show which can be found over on YouTube on rumble and on Odyssey I always have our backups there in case which I think the backups are slowly turning into the the main the main options as things get weirder and weirder. So please guys, make sure you've done me a favor hit that subscribe button. regardless where it is you go ahead and watch the video and do me a favor as well hit that little notification bell so you don't miss a single time we go live so I said at BU Nichols liberty that you can follow me on twitter, facebook true social parlor out our name the website and probably over there. Chad, where can folks go ahead and find you they want continue the conversation.

Chad Harman  27:58  
You can find us on We're on LinkedIn, Twitter, Instagram, Facebook, we're on all those social media outlets. We are a publicly listed company. So we'll send the OTC peek so you can find this number under symbol BW VI or Bluewater ventures Incorporated. We're looking to get that to name and corporate symbol change here very soon with with FINRA, so thanks again.

Brian Nichols  28:27  
Absolutely. All right, folks. Well, if you again, enjoy today's episode, well, I know you're going to enjoy the episode. If you're joining us here on YouTube. That is right here. I'm going to include that that's the video is recommended to you and also over here next to to Chad, over to your right, you're going to find another video I'm going to share that as my conversation with Wiley gray. He was talking about bringing along solutions again, specifically to veterans in the psychedelic space. So I met him for my team over and micro dose there when I was leading that back again, question mark last year two years ago, so I'll make sure I include that there for you guys. And if you haven't had the chance yet, hit subscribe here for The Brian Nichols Show. But with that being said, it's Brian Nichols signing off on The Brian Nichols Show for Chad Harmon. We'll see you tomorrow for listening

Disembodied Voice of Matt Ultan, Vocal Artist Extraordinaire  29:12  
to The Brian Nichols Show. Find more episodes at the Brian Nichols

Transcribed by

Chad HarmanProfile Photo

Chad Harman

Chief Executive Officer of Psycheceutical

Chad Harman is a 25-year health insurance and cannabis executive with unique leadership and diverse experience across operations, manufacturing, finance, product development, IT, sales, and marketing while emphasizing corporate KPIs. Chad’s greatest strength lies in developing focused corporate strategies with detailed execution plans; strong interpersonal skills make him a skilled motivator, while his financial acumen helps him maximize the company’s efficiency and profitability.

Psycheceutical is a bioscience company that has two patented technologies designed to increase the safety and efficacy of psychedelic compounds. The company is focused on developing psychedelic medicines that are safer and more effective. Psycheceutical’s patents solve the dosing problem in the psychedelic space and mitigate harmful and uncomfortable side effects from using these compounds.